| | Variables | Moderate fibrosis, N = 96 | No moderate fibrosis, N = 81 | value |
| | Age at LT, years (IQR) | 55 (46–60) | 56 (49–62) | 0.288 | | Age at TE, years (IQR) | 61 (53–64) | 60 (53–66) | 0.818 | | Donor age, years | 57 (44–68) | 60 (44–67) | 0.971 | | Male, % (n) | 68.1 (64) | 68.7 (55) | 0.945 |
| | Cause of liver disease, % (n) | | Autoimmune liver disease | 8.3 (8) | 14.8 (12) | 0.280 | | NAFLD | 0 | 1.2 (1) | | Alcoholic liver disease | 36.5 (35) | 27.2 (22) | | HCV | 2.1 (2) | 4.9 (4) | | Others | 53.1 (51) | 51.9 (42) |
| | BMI, kg/m2 (IQR) | 28.4 (24–32) | 27.5 (23–32) | 0.870 |
| | BMI category, % (n) | | Normal <25 | 35.4 (34) | 38.3 (31) | 0.737 | | Overweight 25–29.9 | 32.3 (31) | 23.4 (19) | | | Obese ≥30 | 32.3 (31) | 38.3 (31) | |
| | Donors BMI, kg/m2 (IQR) | 26.3 (25–29) | 26 (23–28) | 0.132 |
| | Donors BMI category, % (n) | | Normal <25 | 31.2 (30) | 44.4 (36) | 0.105 | | Overweight 25–29.9 | 55.2 (53) | 39.5 (32) | | Obese ≥30 | 13.5 (13) | 16.0 (13) |
| | Hypertension, % (n) | 72.9 (70) | 55.6 (45) | 0.024 | | Diabetes, % (n) | 41.7 (40) | 35.8 (29) | 0.521 | | Thrombocytes x109/L | 161 (129–221) | 170 (139–219) | 0.540 | | Glucose, mmol/L (IQR) | 6.3 (5–8) | 6 (5.4–6.9) | 0.152 | | Total bilirubin, mg/dL (IQR) | 17 (12–24) | 15 (11–19) | 0.173 | | ALT, U/L (IQR) | 31 (23–49) | 24 (17–33) | <0.001 | | AST, U/L (IQR) | 31 (23–48) | 26 (21–34) | 0.001 | | GGT, U/L (IQR) | 53 (28–127) | 29 (17–43) | <0.001 | | Triglyceride, mmol/L (IQR) | 1.32 (1–1.9) | 1.16 (0.9–1.7) | 0.095 | | Total cholesterol, mmol/L (IQR) | 5.1 (4.4–5.7) | 5.2 (4.5–6.1) | 0.572 | | LDL, mmol/L (IQR) | 3 (2.4–3.5) | 3.2 (2.5–3.8) | 0.133 | | HDL, mmol/L (IQR) | 1.3 (1.1–1.6) | 1.3 (1.1–1.6) | 0.692 | | CRP, mg/L (IQR) | 3.3 (2–6) | 3.1 (1.9–5.8) | 0.892 | | CAP, dB (IQR) | 298 (250–334) | 267 (203–310) | 0.004 |
| | Immunosuppression, % (n) | | Tacrolimus | 62.5 (60) | 80.2 (65) | 0.016 | | Cyclosporine | 37.2 (35) | 21.5 (17) | | Prednisone | 5.2 (5) | 3.7 (3) | | mTOR inhibitor | 1.0 (1) | (0) | | Mycophenolate mofetil | 74.0 (71) | 61.7 (50) | | Azathioprine | 1.0 (1) | 2.5 (2) |
| | Time from LT to TE, years (IQR) | 5 (3–6) | 3 (2–5) | 0.008 |
|
|
LT, liver transplantation; NAFLD, nonalcoholic fatty liver disease; HCV, hepatitis C virus infection; BMI, body mass index; AST, serum aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; CAP, controlled attenuation parameter; TE, transient elastography. |
